Info
AE_SUNITINIB
**explain AEs such as hypertension (30%), yellowish discoloration of skin, dryness, thickness, and/or cracking of skin, depigmentation of hair and/or skin, bleeding complications with epistaxis, fatigue, diarrhea, stomatitis, myelosuppression, CHF, and adrenal insufficiency and hypothyroidism .AETAM **explain the risk of tamoxifen, such as menopausal syndrome of hot flush, arthragia, possible infertility, abnormal LFTs, increased risk of thrombosis, dyslipidemia (f/u Qyear, if TG>500, consider treatment, if 200~500 diet control) and endometrial hyperplasia and possible endometrial cancer but rare **Suggest closely follow-up clinical discomfort s/s and return to clinics if s/s progressed or any suspicious.
Siblings
- AE_ABVD
- AE_ACT
- AE_ALECTINIB
- AE_ALIMTA
- AE_ALPELISIB
- AE_BENDAMUSTINE
- AE_CCRT
- AE_CDK46
- AE_CRIZOINIB
- AE_DABRAFENIB
- AE_ENHERTU
- AE_ERIBULIN
- AE_FOLFOX
- AE_GLIVEC
- AE_HERCEPTIN
- AE_LANREOTIDE
- AE_LAPATINIB
- AE_LAR
- AE_LETROZOLE
- AE_OLAPARIB
- AE_OSIMERTINIB
- AE_PAZOPANIB
- AE_PEMIGATINIB
- AE_PERTUZUMAB
- AE_RAMUCIRUMAB
- AE_RECTAL
- AE_REGORAFENIB
- AE_SORAFENIB
- AE_SUNITINIB
- AE_TAS102
- AE_TAXOTERECDDP
- AE_TOPOTECAN
- AE_UFT
- AE_VEMURAFENIB
- AE_VINORELBINE
- AE_XELOX